Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…dvanced small cell lung carcinoma was treated with carboplatin, etoposide and atezolizumab. After two well-tolerated cycles, he developed…
…Background The combination of atezolizumab and bevacizumab (ATZ/BVZ) therapy has significantly advanced th…
…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…
…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …
…e very limited. For decades, tyrosine kinase inhibitors such as sorafenib and lenvatinib have been the only first-line treatments for adv…
…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…
…hemotherapy (HR=2.35; 95% CI:1.39–3.96) or pembrolizumab versus nivolumab (HR=2.46; 95%CI:1.13–5.36) ( figure 1) also conferred a higher …
…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…
… TNBC (ER-/PR-/HER2-) who received at least one dose of an ICI (pembrolizumab, atezolizumab, nivolumab, or durvalumab) between 2014 and 2025.…
… investigators and staff for their participation in the trials. Atezolizumab was supplied by Roche for the N-02 trial.Trial Registration The…
…e models and select the final prediction model, which predicted atezolizumab efficacy with an area under the curve (AUC) of 0.71 in OAK and …
…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…